Recon: AstraZeneca to buy Fusion in targeted radiation deal valued at $2B; Seelos ALS treatment fails in mid-stage trial

• More than 60% of US abortions in 2023 were done by pill, study shows (Reuters)
• US CDC urges measles vaccinations amid rising cases (Reuters)
• CDER, CBER Post FY 2023 Employee Gains, But Behind User Fee Hiring Goals (Pink Sheet)
• Biden expands women's health research, adds $200 million for sexual, reproductive issues (Reuters)
• The Dog That Didn’t Bark: ODAC Gives Nod To Three Products Despite Negative FDA Reviews (Pink Sheet)
• Regeneron advances antitrust lawsuit against Novartis with appeals court's backing (Fierce Pharma)
• US FDA’s Anti-Misinformation Campaigns Look Safer After Supreme Court Oral Arguments (Pink Sheet)
• She stood between a dangerous drug and a generation of American babies (WTOP)

• EU lawmakers vote to extend exclusivity period for new medicines, softening Commission proposal (Reuters)
• 'Critical' to catch up on measles vaccinations to stem outbreaks, says WHO (Reuters)
• All Eyes On Pricing Model As EU Crunch Time Nears For First Ophthalmic Bevacizumab (Pink Sheet)
• Pakistan Explains Updated Risk-Based Criteria For GCP Inspections (Pink Sheet)
• EMA Presses On With Keenly-Awaited Guidance On How To Use Patient Experience Data (Pink Sheet)
• EU Pharma Reform Passes Major Hurdle, With Big Changes To Data Protection Proposals (Pink Sheet)
• Industry To Scrutinize Proposals On Updating Statutory Pricing Agreement (Pink Sheet)

• In small study, baby aspirin cuts fat buildup in liver disease patients (STAT)
• Wegovy and Zepbound get primetime treatment (STAT)
• Seelos Therapeutics' ALS treatment fails mid-stage study (Reuters)
• As targeted radiation field heats up, AstraZeneca to acquire Fusion Pharmaceuticals in $2 billion deal (STAT)
• Madrigal's $600M offering; PureTech to return $100M to shareholders (Endpoints)
• Highly-awaited PhIII study of Gates-backed tuberculosis vaccine underway (Endpoints)
• Morgan Health, JP Morgan’s healthcare venture, is looking to cut pharma costs next (Endpoints)
• Mid-stage neuroscience startup Engrail raises $157M (Endpoints)
• Crinetics reports second PhIII win for acromegaly drug, eyes 2025 launch (Endpoints)
• With positive PhIII data in hot flashes, Bayer is a step closer to challenging Astellas’ Veozah (Endpoints)
• Bayer to seek approval for menopausal relief drug after third trial win (Reuters)

• ‘An AI foundry’: Nvidia’s Jensen Huang pitches biotech on easy AI, with focus on software going beyond chips (Endpoints)
• Titan Medical to merge with imaging firm Conavi, ending strategic review (MedTech Dive)
• J&J Medtech, Nvidia partner to bring AI to the operating room (MedTech Dive)
• Intuitive details launch plan for new da Vinci 5 robot (MedTech Dive)
• Feeling the Heat (or Cold) – New Draft Guidance Addresses Requirements for Devices that Produce Thermal Effects (FDA Law Blog)
• Artificial Intelligence: US FDA Plans Guidances On Algorithm Bias, Product Development (MedTech Insight)

• UnitedHealth appears to be upping loan offers to providers, after Change cyberattack (STAT)
• Supreme Court questions restricting government efforts to limit Covid-19 misinformation (STAT)
• Novo Nordisk Foundation backs effort to build supercomputer with Nvidia (Endpoints)
• UnitedHealth says advanced over $2 bln in payments to providers (Reuters)